Meanwhile, irAEs induced by PD-1 inhibitors predict a better clinical response by patients with cancer, but the association between irAEs and survival in patients undergoing anti-CTLA-4 therapy remains controversial [8, 29, 57–60], demanding larger size of studies in the future. The gene discussed is CTLA4; the disease is cancer.